ARGX vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ARGX demonstrates strong financial health with a Piotroski F-Score of 6/9, indicating stable fundamentals despite a lack of Altman Z-Score. The company exhibits exceptional revenue growth (74.6% YoY) and a robust profit margin (30.42%), supported by a near-zero debt-to-equity ratio and high liquidity. While earnings declined YoY (-32%), this is likely due to one-time R&D investments and a prior-year anomaly, as evidenced by a massive 856.3% YoY EPS growth and consistent earnings surprises. The stock trades at a premium to its Graham Number ($228.72) and intrinsic value ($137.2), but this is justified by its high growth trajectory and strong analyst consensus. The 52-week price range suggests significant upside potential from current levels.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
ARGX vs MRK: Head-to-Head Comparison
This page compares argenx SE (ARGX) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.